WPC
CORT icon

Wedmont Private Capital’s Corcept Therapeutics CORT Stock Holding History

Wedmont Private Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$395K Buy
3,329
+190
+6% +$20.4K 0.01% 670
2026
Q2 		$288K Buy
+3,139
New +$190K 0.01% 751
2025
Q4 		– Sell
-2,644
Closed -$239K – 812
2025
Q3 		$239K Buy
+2,644
New +$191K 0.01% 690

Other funds holding CORT

VFP
Vilga Financial Planning Fair Lawn, New Jersey $168M AUM 23.03% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
BCG
Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return
RA
Riversedge Advisors Wilmington, Delaware $813M AUM 18.09% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

Wedmont Private Capital's CORT Position: Q3 2026 in Review

Wedmont Private Capital increased its Corcept Therapeutics (CORT) stake by 6.1% in Q3 2026, buying an estimated $20.4K and bringing the position to 3,329 shares worth $395K. The position accounts for 0.01% of the portfolio, ranked #670.

Wedmont Private Capital first reported a position in CORT in Q3 2025 and has held it in 3 quarters since. 12 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Wedmont Private Capital held 3,329 shares of Corcept Therapeutics worth $395K as of Q3 2026.
  • Wedmont Private Capital bought 190 Corcept Therapeutics shares in Q3 2026, an estimated $20.4K.
  • Corcept Therapeutics made up 0.01% of Wedmont Private Capital's portfolio in Q3 2026, its #670 holding.
  • Wedmont Private Capital first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 12 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Wedmont Private Capital's 13F filing for Q3 2026, filed 9 Oct 2026.